Publiziert in: Marktpuls, Unternehmen
Frei

THERAMetrics holding AG (SIX: TMX) announces today its half-year interim financial results 2014 Freitag, 26. September 2014 - 20:01

Stans, Switzerland - September 26, 2014

THERAMetrics holding AG (SIX: TMX, "THERAMetrics" or the "Company") today published its 2014 half-year interim financial results.

For the half year ended 30 June 2014 the Company and its subsidiaries (the “Group”) generated revenues of EUR 8.2 million (H1 2013: EUR 9.8 million) and incurred operating expenses of EUR 11.9 million (H1 2013: EUR 12.2 million), resulting in EBITDA of negative EUR 3.6 million (H1 2013: negative EUR 2.4 million). The net loss of EUR 8.0 million (H1 2013: net loss of EUR 2.7 million) results in negative earnings per share of EUR 0.014 (H1 2013: EUR 0.012).

The Interim Financial Results are available here.

After the successful capital increase concluded on 12 September, and in light of the on-going restructuring and cost-cutting measures, management feels the Company is now well positioned to return to a period of growth and operational stability.

Going forward, the Company will focus its operation on its core strengths as follows:

  • The development of various options for the commercialization of our bio-mathematical platform for drug rescuing and repurposing DRR2.0. The Company is already in discussions with different interested life sciences companies to define commercial terms of potential collaborations.
  • Phase I and II clinical trials - These are less cash intensive and have shorter revenue cycles compared to Phase III and IV projects, which tend to be cash intensive with longer revenue cycles. A new business development team will be built to focus on these projects.
  • Growing the IMP business, which the Company believes has solid growth potential.

In addition, the Company will focus on licensing its intellectual property portfolio.

About THERAMetrics
Therametrics holding AG is a global tech-based Contract Research & Development Organisation dedicated to provide a full range of technological solutions through the entire value chain of drug discovery and development. The company, listed at the SIX Swiss Exchange (TMX), is headquartered in Stans (Switzerland). 

For further information please contact
THERAMetrics holding AG
Investor and External Relations
Tel.: +41 79 37 19 184
investor@therametrics.com
www.therametrics.com

Swiss media relation:
Fiorenzo Fässler
SRI Management Consulting SA
0041-795115750 (mobile); 0041 432996930
faessler@sriconsulting.ch

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning THERAMetrics holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of THERAMetrics holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. THERAMetrics holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.